Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

Visibly Digital Acuity Product

K-Number: K220090 · 2022-08-12

ApplicantVisibly, Inc.
Decision Date2022-08-12
Product CodeQTO
Advisory CommitteeOP
DecisionSubstantially Equivalent

Device Summary

Visibly Digital Acuity Product is the device name listed in this FDA 510(k) record. The listed applicant is Visibly, Inc.. It received FDA 510(k) clearance on 2022-08-12 under 510(k) number K220090. The device is classified under product code QTO. It was reviewed by the OP advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the Visibly Digital Acuity Product?

Visibly Digital Acuity Product is a medical device that received FDA 510(k) clearance on 2022-08-12. The listed applicant is Visibly, Inc.. The 510(k) number is K220090.

When did Visibly Digital Acuity Product receive FDA 510(k) clearance?

Visibly Digital Acuity Product received FDA 510(k) clearance on 2022-08-12, under 510(k) number K220090.

Who is the listed applicant for Visibly Digital Acuity Product?

The FDA 510(k) record lists Visibly, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Visibly Digital Acuity Product?

The FDA product code for Visibly Digital Acuity Product is QTO.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑